



European Society for Medical Oncology (ESMO) 2020

Virtual Congress, 19-21 September 2020

Copies of e-posters obtained through QR codes are for personal use only and may not be reproduced without written permission of the authors

Index of GSK posters at ESMO 2020

Please click on the titles below to view and download the posters

Thursday 17 September 2020

Efficacy and Safety of Niraparib in Older Patients With Advanced Ovarian Cancer: Results From the PRIMA/ENGOT-OV26/GOG-3012 Trial

Giorgio Valabrega,¹ Bhavana Pothuri,² Ana Oaknin,³ Whitney Graybill,⁴ Ana Beatriz Sánchez,⁵ Colleen McCormick,⁶ Jean-François Baurain,⁷ Paul Hoskins,⁸ Hannelore Denys,⁹ Roisin E. O’Cearbhaill,¹⁰ Sakari Hietanen,¹¹ Richard G. Moore,¹² Anja Ør Knudsen,¹³ Thibault de La Motte Rouge,¹⁴ Florian Heitz,¹⁵ Tally Levy,¹⁶ Yong Li,¹⁷ Divya Gupta,¹⁷ Bradley J. Monk,¹⁸ Antonio González-Martín¹⁹

MOONSTONE/GOG-3032: A Phase 2, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Niraparib + Dostarlimab in Patients with Platinum-Resistant Ovarian Cancer

Leslie M. Randall¹, David M. O’Malley², Bradley J. Monk³, Robert L. Coleman⁴, Roisin E. O’Cearbhaill⁵, Stephanie Gaillard⁶, Sarah Adams⁷, Fabio Cappuccini⁸, Marilyn Huang⁹, Hye Sook Chon¹⁰, Angeles Alvarez Secord¹¹, Sujata Arora¹², Erika Keeton¹², Divya Gupta¹², Vivek Samnotra¹², Panagiotis Konstantinopoulos¹³

JASPER: Efficacy and Safety of First-Line (1L) Niraparib Plus a Programmed Death Receptor 1 Inhibitor (PD-1i) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Suresh S. Ramalingam¹, Eddie Thara², Mark M. Awad³, Afshin Dowlati⁴, Basir Haque⁵, Thomas Stinchcombe⁶, Grace K. Dy⁷, David R. Spigel⁸, Nithya Iyer Singh⁹, Lena Evilevitch⁹, Zhaojie Wang⁹, Yongqiang Tang⁹, Iryna Teslenko⁹, Mahua Roychoudhury⁹

Patient-Reported Outcomes (PROs) in the GARNET Trial in Patients With Advanced or Recurrent Mismatch Repair Deficient/Microsatellite Instability-High (dMMR/MSI-H) Endometrial Cancer (EC) Treated With Dostarlimab

Rebecca Kristeleit,¹ Cara Mathews,² Andrés Redondo,³ Joice Huang,⁴ Laurie Eliason,⁴ Ellie Im,⁴ Jubilee Brown⁵

Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non-Small Cell Lung Cancer (NSCLC)

Janakiraman Subramanian,¹ Victor Moreno,² Joaquim Bosch Barrera,³ Joanna Pikiel,⁴ Rebecca Kristeleit,⁵ Wei Guo,⁶ Hadi Danaee,⁶ Ellie Im,⁶ Desamparados Roda⁷

Matching-Adjusted Indirect Comparisons (MAIC) of Safety Between Single-Agent Belantamab Mafodotin Versus Selinexor Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM)

Attaya Suvannasankha^{1*}, Thibaud Prawitz², Venediktos Kapetanakis³, Grammati Sarri^{3†}, Rachel Hughes⁴, Feng Wang⁵, Cosmina Hoge⁵, Shannon Allen Ferrante⁵, Ben Gutierrez⁵, Boris Gorsh⁵, Jenny Willson⁶, Rakesh Popat⁷

The Relationship Between Overall Survival (OS), Progression-Free Survival (PFS), and Objective Response Rate (ORR) in Immune Checkpoint Inhibitor Clinical Trials of Head and Neck Squamous Cell Carcinoma (HNSCC): A Systematic Review and Meta-analysis

Wang X¹, Ballas M¹, Chen H¹, Bell KF¹, Slowley A², Ellis C¹, Turner DC¹, Zhou H¹

[About us](#)

[Contact us](#)

[Terms of use](#)

[Privacy statement](#)

[Cookies policy](#)